Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Effect of Mesenchymal Stem Cell Secretome on Inflammation Activity and Markers in Sjogren Syndrome: A Randomized, Placebo-Controlled, Double-Blind Trial

NCT07910526 is registered in ClinicalTrials.gov with Universitas Sebelas Maret Hospital as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07910526 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
The Effect of Mesenchymal Stem Cell Secretome on Inflammation Activity and Markers in Sjogren Syndrome: A Randomized, Placebo-Controlled, Double-Blind Trial
Lead sponsor
Universitas Sebelas Maret Hospital
Phase
Phase 1/2
Overall status
Completed
Start date
May 1, 2024
Completion date
October 20, 2026
Enrollment
29 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

Arms

As registered; 2 arms.

  • UC-MSC Secretome ExperimentalUmbilical cord mesenchymal stem cell-derived secretome
  • Placebo (0.9% NaCl) Placebo comparatorPlacebo (0.9% sodium chloride)

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Change in EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) score Baseline (before first injection), Day 22 and Day 43

Lead sponsor's other trials

Universitas Sebelas Maret Hospital, most recent start first.

Similar trials

Same condition (Sjogren's Syndrome) and phase, most recent start first.